GlassScriptPhysician profile
Matthew Warren Doty
NPI 1538528674
$3,147.52
in general payments reported to CMS, 2019-2025
19 companies · $229 in 2025
The $229 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.39 · 2021: $1,384 · 2022: $133 · 2023: $1,046 · 2024: $336 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,019 · Food and Beverage: $592.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,019.16 |
| Food and Beverage | $591.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,135.44 | 2022-2024 | Proclaim, Octrode |
| Spinal Simplicity, LLC | $844.55 | 2021 | |
| Boston Scientific Corporation | $310.79 | 2024-2025 | Superion Indirect Decompression System, Intracept |
| Medtronic, INC. | $284.31 | 2021 | |
| Relievant Medsystems, INC. | $130.66 | 2021 | |
| Nalu Medical, INC. | $124.97 | 2021 | |
| Abiomed | $124.14 | 2025 | |
| Novo Nordisk INC | $80.26 | 2022 | |
| Stryker Corporation | $27.21 | 2023 | Spinejack |
| Verona Pharma, INC. | $26.70 | 2025 | Ohtuvayre |
| Genentech USA, INC. | $20.92 | 2024 | Xolair |
| Amgen INC. | $19.39 | 2019 | |
| Glaxosmithkline, LLC. | $18.18 | 2022 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Doty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.